merck serono
Merck & BeiGene To Co-Develop 2nd Gen BRAF Inhibitor
Merck Serono and BeiGene have agreed to co-develop a second-generation BRAF inhibitor for the treatment of cancer.
Merck Serono and BeiGene have agreed to co-develop a second-generation BRAF inhibitor for the treatment of cancer.
